For Institutions
About
Fosun Pharma Industrial is acquiring a majority stake in an Alzheimer's drug developer for RMB1.27 billion. The deal includes purchasing 8.6667% equity from Shiyin Investment and Shibirun for RMB143 million, and subscribing to new capital for a 46.3504% stake. A special purpose vehicle will be formed with a 51% stake held by Fosun Pharma. The acquisition aims to enhance Fosun Pharma's market position and advance Alzheimer's treatment development.
Fosun Pharma Seeks Approval for New Indication of Cancer Drug
